Abstract: This present disclosure relates to the technical field of artificial intelligence, and provides a vessel image classification method and apparatus, a device, and a storage medium. The method includes: inputting a first vessel image sample into a first image processing model, and obtaining a predicted enhanced image and predicted vessel location information; and training the first image processing model based on a second vessel image sample, vessel location labeling information, the predicted enhanced image, and the predicted vessel location information. In the above solution, the impact of image quality on the vessel classification is considered during training of the vessel classification model, so that an end-to-end vessel classification model subsequently generated based on the trained first image processing model can realize a higher classification accuracy for a low quality vessel image, thereby improving the accuracy of classifying vessels in the vessel image by artificial intelligence.

Abstract: A method for storing database security audit records, comprises: S1, when a database server recognizes an auditable event to generate one database security audit record, identifying the database security audit record with a hashed value so that each database security audit record corresponds to a unique hashed value respectively; S2, packaging multiple database security audit records into a database security audit record block; and S3, transmitting the database security audit record block in encrypted way by adopting a peer-to-peer protocol for direct network communication between two nodes, and verifying an ownership of the database security audit record block. The disclosure has the beneficial effects that through an encryption mechanism and a consensus mechanism, storage of database security audit records is achieved in a peer-to-peer network, thereby ensuring that the database security audit records cannot be tampered and forged.

Abstract: A heterocyclic compound as a Syk inhibitor and/or a Syk-HDAC dual inhibitor, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof are provided. Specifically, a compound of formula (I) is provided, which has dual inhibitory activity for Syk and/or Syk-HDAC.

Abstract: A heterocyclic compound as a Syk inhibitor and/or a Syk-HDAC dual inhibitor, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof are provided. Specifically, a compound of formula (I) is provided, which has dual inhibitory activity for Syk and/or Syk-HDAC.

Abstract: A method for storing database security audit records, comprises: S1, when a database server recognizes an auditable event to generate one database security audit record, identifying the database security audit record with a hashed value so that each database security audit record corresponds to a unique hashed value respectively; S2, packaging multiple database security audit records into a database security audit record block; and S3, transmitting the database security audit record block in encrypted way by adopting a peer-to-peer protocol for direct network communication between two nodes, and verifying an ownership of the database security audit record block. The disclosure has the beneficial effects that through an encryption mechanism and a consensus mechanism, storage of database security audit records is achieved in a peer-to-peer network, thereby ensuring that the database security audit records cannot be tampered and forged.

Abstract: A heterocyclic compound as a Syk inhibitor and/or a Syk-HDAC dual inhibitor, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof are provided. Specifically, a compound of formula (I) is provided, which has dual inhibitory activity for Syk and/or Syk-HDAC.

Abstract: A high precision high reliability and quick response thermosensitive chip and manufacturing method thereof is provided, including a thermosensitive ceramic semiconductor substrate; glass protective layers are alternately spray-coated and sintered on the two surfaces of the thermosensitive ceramic semiconductor substrate; and the two surfaces of the thermosensitive ceramic semiconductor substrate having the glass protective layers are printed with metal electrode layers. The thermosensitive chip achieves quick response, accurate control of resistance precision and has high precision; in addition, the glass protective layers thereof enable the thermosensitive chip to have high reliability.

Abstract: The present application relates to the technical field of ultrafast imaging, and provides an ultrafast framing optical imaging device with a real-time high spatial resolution. The optical imaging device includes an ultrashort pulse laser system with a magnitude of femtosecond, a frequency multiplier, a wavelength splitter, a continuous illumination laser, a sampling plate, a calibration camera, a first imaging record module, and a second imaging record module. The present application mainly utilizes continuous light illumination ultrafast events and non-collinear light parameter amplifying technology that uses ultrashort pulse laser to pump/sample events at different moments, and adopts a plurality of CCD cameras to receive corresponding idle light images simultaneously and respectively and thereby realize ultrafast framing optical imaging with a high time resolution.

Abstract: A high precision high reliability and quick response thermosensitive chip and manufacturing method thereof is provided, including a thermosensitive ceramic semiconductor substrate; glass protective layers are alternately spray-coated and sintered on the two surfaces of the thermosensitive ceramic semiconductor substrate; and the two surfaces of the thermosensitive ceramic semiconductor substrate having the glass protective layers are printed with metal electrode layers. The thermosensitive chip achieves quick response, accurate control of resistance precision and has high precision; in addition, the glass protective layers thereof enable the thermosensitive chip to have high reliability.

Abstract: The present application relates to the technical field of ultrafast imaging, and provides an ultrafast framing optical imaging device with a real-time high spatial resolution. The optical imaging device includes an ultrashort pulse laser system with a magnitude of femtosecond, a frequency multiplier, a wavelength splitter, a continuous illumination laser, a sampling plate, a calibration camera, a first imaging record module, and a second imaging record module. The present application mainly utilizes continuous light illumination ultrafast events and non-collinear light parameter amplifying technology that uses ultrashort pulse laser to pump/sample events at different moments, and adopts a plurality of CCD cameras to receive corresponding idle light images simultaneously and respectively and thereby realize ultrafast framing optical imaging with a high time resolution.

Abstract: The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I

Abstract: The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

Abstract: The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I

Abstract: The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

Abstract: The present invention is directed to novel compounds represented by structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R4a, R5, R6, R7, R8, R9,and m, are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain central nervous system disorders. The compounds of this invention are serotonin receptor modulators, in particular 5HT2C receptor agonists and antagonists, and are useful in the control or prevention of central nervous system disorders including obesity, anorexia, bulemia, depression, anxiety, psychosis, schizophrenia, migraine, addictive behavior, obsessive-compulsive disorder, and sexual disorders.

Abstract: The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

Abstract: The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.